AU2018342471B2 - Salts of pyrrolotriazine derivatives useful as TAM inhibitors - Google Patents

Salts of pyrrolotriazine derivatives useful as TAM inhibitors Download PDF

Info

Publication number
AU2018342471B2
AU2018342471B2 AU2018342471A AU2018342471A AU2018342471B2 AU 2018342471 B2 AU2018342471 B2 AU 2018342471B2 AU 2018342471 A AU2018342471 A AU 2018342471A AU 2018342471 A AU2018342471 A AU 2018342471A AU 2018342471 B2 AU2018342471 B2 AU 2018342471B2
Authority
AU
Australia
Prior art keywords
salt
compound
phenyl
cancer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018342471A
Other languages
English (en)
Other versions
AU2018342471A1 (en
Inventor
Zhongjiang JIA
Qun Li
Yongchun Pan
Yongzhong Wu
Jiacheng Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2018342471A1 publication Critical patent/AU2018342471A1/en
Application granted granted Critical
Publication of AU2018342471B2 publication Critical patent/AU2018342471B2/en
Priority to AU2023270198A priority Critical patent/AU2023270198A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018342471A 2017-09-27 2018-09-26 Salts of pyrrolotriazine derivatives useful as TAM inhibitors Active AU2018342471B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023270198A AU2023270198A1 (en) 2017-09-27 2023-11-20 Salts of pyrrolotriazine derivatives useful as tam inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762564070P 2017-09-27 2017-09-27
US62/564,070 2017-09-27
US201862714196P 2018-08-03 2018-08-03
US62/714,196 2018-08-03
PCT/US2018/052925 WO2019067594A1 (en) 2017-09-27 2018-09-26 SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023270198A Division AU2023270198A1 (en) 2017-09-27 2023-11-20 Salts of pyrrolotriazine derivatives useful as tam inhibitors

Publications (2)

Publication Number Publication Date
AU2018342471A1 AU2018342471A1 (en) 2020-04-23
AU2018342471B2 true AU2018342471B2 (en) 2023-08-24

Family

ID=63794769

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018342471A Active AU2018342471B2 (en) 2017-09-27 2018-09-26 Salts of pyrrolotriazine derivatives useful as TAM inhibitors
AU2023270198A Pending AU2023270198A1 (en) 2017-09-27 2023-11-20 Salts of pyrrolotriazine derivatives useful as tam inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023270198A Pending AU2023270198A1 (en) 2017-09-27 2023-11-20 Salts of pyrrolotriazine derivatives useful as tam inhibitors

Country Status (35)

Country Link
US (4) US10633387B2 (enExample)
EP (2) EP3687996B1 (enExample)
JP (3) JP7504791B2 (enExample)
KR (1) KR102739325B1 (enExample)
CN (2) CN111386273B (enExample)
AU (2) AU2018342471B2 (enExample)
BR (1) BR112020006145A2 (enExample)
CA (1) CA3077308A1 (enExample)
CL (2) CL2020000791A1 (enExample)
CO (1) CO2020005009A2 (enExample)
CR (1) CR20200179A (enExample)
CY (1) CY1124952T1 (enExample)
DK (1) DK3687996T3 (enExample)
EC (1) ECSP20021655A (enExample)
ES (1) ES2904458T3 (enExample)
GE (1) GEP20227429B (enExample)
HU (1) HUE057190T2 (enExample)
IL (1) IL273579B2 (enExample)
JO (1) JOP20200081A1 (enExample)
LT (1) LT3687996T (enExample)
MA (1) MA50655B1 (enExample)
MD (1) MD3687996T2 (enExample)
MX (1) MX2020003375A (enExample)
MY (1) MY208007A (enExample)
PE (1) PE20210002A1 (enExample)
PH (1) PH12020550143A1 (enExample)
PL (1) PL3687996T3 (enExample)
PT (1) PT3687996T (enExample)
RS (1) RS62872B1 (enExample)
SA (1) SA520411638B1 (enExample)
SG (1) SG11202002821UA (enExample)
SI (1) SI3687996T1 (enExample)
SM (1) SMT202200011T1 (enExample)
TW (1) TWI821200B (enExample)
WO (1) WO2019067594A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
LT3386591T (lt) 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
WO2017172596A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
ES2975336T3 (es) 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
CA3077308A1 (en) 2017-09-27 2019-04-04 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
PL3813800T3 (pl) 2018-06-29 2025-08-18 Incyte Corporation Formulacje inhibitora axl/mer
ES2951872T3 (es) 2018-08-03 2023-10-25 Novartis Ag Moduladores del receptor NMDA heteroaromáticos y usos de los mismos
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
JP7556604B2 (ja) * 2020-07-10 2024-09-26 範恩柯爾生物科技（中山）有限公司 トリアジン系化合物およびその組成物と用途
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
EP4371978A4 (en) * 2021-07-13 2025-09-10 Nippon Soda Co PROCESS FOR PRODUCING A URACIL COMPOUND

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172596A1 (en) * 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0395163A (ja) 1989-09-08 1991-04-19 Daicel Chem Ind Ltd ２．２．４．４．６―ペンタメチル―２．３．４．５―テトラヒドロピリミジンの製造法
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
SK3792002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Kinase inhibitors as therapeutic agents
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
PL363991A1 (en) 2001-04-06 2004-11-29 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
WO2004035580A1 (en) 2002-10-21 2004-04-29 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
EP2186510B1 (en) 2003-03-26 2013-07-10 Egalet Ltd. Matrix compositions for controlled delivery of drug substances
JP4667383B2 (ja) 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
US20050203063A1 (en) 2003-09-12 2005-09-15 Raymond Deshaies Proteasome pathway inhibitors and related methods
DE602005014964D1 (de) 2004-04-02 2009-07-30 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
PT2385053E (pt) 2005-11-17 2013-12-17 Osi Pharm Inc Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MX2008007103A (es) 2005-12-02 2008-09-12 Bayer Healthcare Llc Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis.
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
JP5313875B2 (ja) 2006-04-12 2013-10-09 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患の処置のためのタンパク質キナーゼｐｌｋ１の阻害剤として有用な４，５−ジヒドロ−［１，２，４］トリアゾロ［４，３−ｆ］プテリジン
PE20080359A1 (es) 2006-04-19 2008-06-06 Novartis Ag Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
JP2009537632A (ja) 2006-05-19 2009-10-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト 過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
CA2672612A1 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
ME01832B (me) 2006-12-29 2014-12-20 Rigel Pharmaceuticals Inc Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori
ES2607065T3 (es) 2006-12-29 2017-03-29 Rigel Pharmaceuticals, Inc. Triazoles N3-heteroaril sustituidos y triazoles N5-heteroaril sustituidos útiles como inhibidores de axl
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
NZ579811A (en) 2007-03-29 2012-02-24 Panacea Biotec Ltd Modified dosage forms of tacrolimus
SI2003120T1 (sl) 2007-06-12 2010-03-31 Concert Pharmaceuticals Inc Azapeptidni derivati kot inhibitorji hiv proteaze
CA2695753A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
JP5635909B2 (ja) 2007-10-26 2014-12-03 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な多環アリール置換トリアゾール及び多環ヘテロアリール置換トリアゾール
US8841312B2 (en) 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
CN102131783A (zh) 2008-04-16 2011-07-20 马克斯普朗克科学发展组织 作为axl激酶抑制剂的喹啉衍生物
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
KR20110039278A (ko) 2008-06-23 2011-04-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제
CA2730231C (en) 2008-07-09 2016-10-18 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2730251C (en) 2008-07-09 2016-08-09 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
US20100075973A1 (en) 2008-08-28 2010-03-25 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
EP2393814A1 (en) 2009-02-09 2011-12-14 SuperGen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
HRP20140754T2 (hr) 2009-06-29 2015-07-17 Incyte Corporation Pirimidinoni kao inhibitori pi3k
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR20120096474A (ko) 2009-09-25 2012-08-30 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CN102918045A (zh) 2010-03-31 2013-02-06 百时美施贵宝公司 作为蛋白激酶抑制剂的取代的吡咯并三嗪
AU2010352577A1 (en) 2010-05-05 2012-01-19 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as PKC-theta inhibitors
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
EP2661268A2 (en) 2010-10-08 2013-11-13 Elan Pharmaceuticals Inc. Inhibitors of polo-like kinase
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
MY181439A (en) 2011-02-28 2020-12-22 Sunshine Lake Pharma Co Ltd Substituted quinoline compounds and methods of use
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
PT2693881T (pt) 2011-04-01 2019-12-09 Univ Utah Res Found Análogos de n-fenilpirimidin-2-amina substituídos como inibidores da axl cinase
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
PH12013502695A1 (en) 2011-07-01 2019-06-14 Bayer Ip Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
LT3196202T (lt) 2011-09-02 2019-07-10 Incyte Holdings Corporation Heterociklilaminai, kaip pi3k slopikliai
EA028413B1 (ru) 2011-09-18 2017-11-30 Эро-Селтик С.А. Фармацевтические композиции
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
UY34451A (es) 2011-11-14 2013-05-31 Cephalon Inc Derivados de uracilo como inhibidores de la quinasa axl y c-met
WO2013082210A1 (en) 2011-11-29 2013-06-06 Perosphere Inc. Anticoagulant reversal agents
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
PT2810937T (pt) 2012-01-31 2017-03-03 Daiichi Sankyo Co Ltd Derivado de piridona
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
WO2013162061A1 (ja) 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
WO2014039714A2 (en) 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RU2015115631A (ru) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
JP6218848B2 (ja) 2012-11-20 2017-10-25 プロキナーゼ ゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのチオエーテル誘導体
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US9012466B2 (en) 2013-03-12 2015-04-21 Arqule Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
EP3067356B1 (en) 2013-11-08 2018-07-04 ONO Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
WO2015081783A1 (zh) 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
TWI542588B (zh) 2014-02-03 2016-07-21 卡迪拉保健有限公司 新穎雜環化合物
GB201420285D0 (en) 2014-11-14 2014-12-31 Bergenbio As Process
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
CN116333138A (zh) 2015-07-30 2023-06-27 宏观基因有限公司 Pd-1结合分子和其使用方法
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
US20180296561A1 (en) 2015-10-07 2018-10-18 The University Of North Carolina At Chapel Hill The Methods For Treatment Of Tumors
AU2016337957B2 (en) 2015-10-13 2018-11-08 Nihon Nohyaku Co., Ltd. Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound, and method for using the insecticide
EP3373934B1 (en) 2015-11-14 2020-05-20 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
EP3373932B1 (en) 2015-11-14 2022-03-30 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
TW201803871A (zh) * 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
EP3484524B1 (en) 2016-07-15 2022-11-09 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of smn2
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
CA3077308A1 (en) 2017-09-27 2019-04-04 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
PL3813800T3 (pl) * 2018-06-29 2025-08-18 Incyte Corporation Formulacje inhibitora axl/mer
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172596A1 (en) * 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors

Also Published As

Publication number Publication date
PH12020550143A1 (en) 2020-12-07
WO2019067594A1 (en) 2019-04-04
IL273579B2 (en) 2025-10-01
TWI821200B (zh) 2023-11-11
ES2904458T3 (es) 2022-04-05
CL2020000791A1 (es) 2020-09-25
IL273579B1 (en) 2025-06-01
EP3687996B1 (en) 2021-11-03
SMT202200011T1 (it) 2022-03-21
CR20200179A (es) 2020-11-02
PT3687996T (pt) 2022-01-21
GEP20227429B (en) 2022-10-25
CL2022001014A1 (es) 2022-11-18
DK3687996T3 (da) 2022-01-10
LT3687996T (lt) 2022-01-10
CN111386273B (zh) 2024-06-14
CO2020005009A2 (es) 2020-05-29
CA3077308A1 (en) 2019-04-04
SA520411638B1 (ar) 2024-03-28
MY208007A (en) 2025-04-04
CN111386273A (zh) 2020-07-07
MD3687996T2 (ro) 2022-04-30
RS62872B1 (sr) 2022-02-28
US11104682B2 (en) 2021-08-31
JOP20200081A1 (ar) 2020-04-30
CN118930549A (zh) 2024-11-12
EP3988552A1 (en) 2022-04-27
KR20200088308A (ko) 2020-07-22
US20250188086A1 (en) 2025-06-12
CY1124952T1 (el) 2023-01-05
PE20210002A1 (es) 2021-01-05
US20220227770A1 (en) 2022-07-21
JP2020535168A (ja) 2020-12-03
US20200347065A1 (en) 2020-11-05
MX2020003375A (es) 2020-08-03
MA50655A (fr) 2021-06-02
MA50655B1 (fr) 2021-11-30
SG11202002821UA (en) 2020-04-29
US10633387B2 (en) 2020-04-28
PL3687996T3 (pl) 2022-02-21
SI3687996T1 (sl) 2022-04-29
IL273579A (en) 2020-05-31
JP7639195B2 (ja) 2025-03-04
EP3687996A1 (en) 2020-08-05
TW201920186A (zh) 2019-06-01
JP2024059647A (ja) 2024-05-01
HUE057190T2 (hu) 2022-04-28
US20190112313A1 (en) 2019-04-18
AU2018342471A1 (en) 2020-04-23
JP7504791B2 (ja) 2024-06-24
JP2025093936A (ja) 2025-06-24
US12187730B2 (en) 2025-01-07
ECSP20021655A (es) 2020-07-31
KR102739325B1 (ko) 2024-12-09
AU2023270198A1 (en) 2023-12-14
BR112020006145A2 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
US12187730B2 (en) Salts of TAM inhibitors
AU2024201172C1 (en) Pyrrolotriazine compounds as tam inhibitors
HK40072676A (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
HK40034398A (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
HK40034398B (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
EA041099B1 (ru) Соли производных пирролотриазинов, пригодных для использования в качестве ингибиторов tam
HK40109049A (en) Pyrrolotriazine compounds as tam inhibitors
HK40002977B (en) Pyrrolotriazine compounds as tam inhibitors
HK40002977A (en) Pyrrolotriazine compounds as tam inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)